Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become

Eli Lilly discontinued development of a new GLP-1 weight-loss drug that failed to meet efficacy expectations. While GLP-1 drugs (Mounjaro, Zepbound, Foundayo) account for over 65% of the company's revenue, Eli Lilly is strategically preparing for future patent expirations by aggressively investing in its drug pipeline through acquisitions and in-house research, particularly in infectious diseases. The company's willingness to cut underperforming candidates and move quickly on acquisitions demonstrates strong long-term strategic positioning.